Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Pancreatic Neoplasms 7Colorectal Neoplasms 6Small Cell Lung Carcinoma 3Stomach Neoplasms 2Solid Tumor Cancer 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Recurrence 1Rectal Cancer Patients 1PDAC - Pancreatic Ductal Adenocarcinoma 1Ovarian Neoplasms 1Osteosarcoma 1Neoplasm Metastasis 1Neoadjuvant Chemotherapy 1Fallopian Tube Neoplasms 1Esophageal Squamous Cell Carcinoma 1Esophageal Neoplasms 1Efficacy and Safety 1Carcinoma, Ovarian Epithelial 1Advanced Small Intestine Cancer 1

Interventions

Paclitaxel 4Topotecan 3liposomal doxorubicin 2Carboplatin 2irinotecan sucrosofate 1fluzoparib 1anlotinib 1Surgical Procedures, Operative 1Specimen Handling 1Poly A 1Neoadjuvant Therapy 1Magnetic Resonance Spectroscopy 1Losartan 1Gemcitabine 1Drug Therapy 1Doxorubicin 1Bevacizumab 1Angiogenesis Inhibitors 1Albumin-Bound Paclitaxel 1Adenosine Diphosphate Ribose 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Fallopian Tube Neoplasms × irinotecan sucrosofate × Clear all
NCT07591831 2026-05-18

Liposomal Irinotecan Plus Enlonstobart for Platinum-Resistant Recurrent Ovarian Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Not yet recruiting
30 enrolled
Gynecologic

Carcinoma, Ovarian Epithelial, Fallopian Tube Neoplasms, Ovarian Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡